625 related articles for article (PubMed ID: 37161995)
1. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
Xie Y; Choi T; Al-Aly Z
BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
[TBL] [Abstract][Full Text] [Related]
2. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition.
Xie Y; Choi T; Al-Aly Z
JAMA Intern Med; 2023 Jun; 183(6):554-564. PubMed ID: 36951829
[TBL] [Abstract][Full Text] [Related]
3. Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
Xie Y; Bowe B; Al-Aly Z
BMJ; 2023 Apr; 381():e073312. PubMed ID: 37041016
[TBL] [Abstract][Full Text] [Related]
4. Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records.
Xie Y; Bowe B; Al-Aly Z
BMJ; 2023 Mar; 380():e072705. PubMed ID: 36882199
[TBL] [Abstract][Full Text] [Related]
5. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
6. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study.
Xu E; Xie Y; Al-Aly Z
Lancet Diabetes Endocrinol; 2023 Feb; 11(2):120-128. PubMed ID: 36623520
[TBL] [Abstract][Full Text] [Related]
7. Associations between post-acute sequelae of SARS-CoV-2, COVID-19 vaccination and HIV infection: a United States cohort study.
Yendewa GA; Perez JA; Patil N; McComsey GA
Front Immunol; 2024; 15():1297195. PubMed ID: 38318191
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
LaVergne SM; Stromberg S; Baxter BA; Webb TL; Dutt TS; Berry K; Tipton M; Haberman J; Massey BR; McFann K; Alnachoukati O; Zier L; Heacock T; Ebel GD; Henao-Tamayo M; Dunn J; Ryan EP
BMC Infect Dis; 2021 Jul; 21(1):677. PubMed ID: 34256735
[TBL] [Abstract][Full Text] [Related]
10. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study.
Cohen K; Ren S; Heath K; Dasmariñas MC; Jubilo KG; Guo Y; Lipsitch M; Daugherty SE
BMJ; 2022 Feb; 376():e068414. PubMed ID: 35140117
[TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
12. Risks and burdens of incident diabetes in long COVID: a cohort study.
Xie Y; Al-Aly Z
Lancet Diabetes Endocrinol; 2022 May; 10(5):311-321. PubMed ID: 35325624
[TBL] [Abstract][Full Text] [Related]
13. Frailty as a risk factor for post-acute sequelae of COVID-19 among US veterans during the Delta and Omicron waves.
Hammel IS; Tosi DM; Tang F; Pott H; Ruiz JG
J Am Geriatr Soc; 2023 Dec; 71(12):3826-3835. PubMed ID: 37725480
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir.
Chen PC; Huang CC; Fu CM; Chang YC; Wu PJ; Lee WC; Lee CT; Tsai KF
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851757
[TBL] [Abstract][Full Text] [Related]
16. Risks of mental health outcomes in people with covid-19: cohort study.
Xie Y; Xu E; Al-Aly Z
BMJ; 2022 Feb; 376():e068993. PubMed ID: 35172971
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
18. Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection.
Thaweethai T; Jolley SE; Karlson EW; Levitan EB; Levy B; McComsey GA; McCorkell L; Nadkarni GN; Parthasarathy S; Singh U; Walker TA; Selvaggi CA; Shinnick DJ; Schulte CCM; Atchley-Challenner R; Alba GA; Alicic R; Altman N; Anglin K; Argueta U; Ashktorab H; Baslet G; Bassett IV; Bateman L; Bedi B; Bhattacharyya S; Bind MA; Blomkalns AL; Bonilla H; Brim H; Bush PA; Castro M; Chan J; Charney AW; Chen P; Chibnik LB; Chu HY; Clifton RG; Costantine MM; Cribbs SK; Davila Nieves SI; Deeks SG; Duven A; Emery IF; Erdmann N; Erlandson KM; Ernst KC; Farah-Abraham R; Farner CE; Feuerriegel EM; Fleurimont J; Fonseca V; Franko N; Gainer V; Gander JC; Gardner EM; Geng LN; Gibson KS; Go M; Goldman JD; Grebe H; Greenway FL; Habli M; Hafner J; Han JE; Hanson KA; Heath J; Hernandez C; Hess R; Hodder SL; Hoffman MK; Hoover SE; Huang B; Hughes BL; Jagannathan P; John J; Jordan MR; Katz SD; Kaufman ES; Kelly JD; Kelly SW; Kemp MM; Kirwan JP; Klein JD; Knox KS; Krishnan JA; Kumar A; Laiyemo AO; Lambert AA; Lanca M; Lee-Iannotti JK; Logarbo BP; Longo MT; Luciano CA; Lutrick K; Maley JH; Marathe JG; Marconi V; Marshall GD; Martin CF; Matusov Y; Mehari A; Mendez-Figueroa H; Mermelstein R; Metz TD; Morse R; Mosier J; Mouchati C; Mullington J; Murphy SN; Neuman RB; Nikolich JZ; Ofotokun I; Ojemakinde E; Palatnik A; Palomares K; Parimon T; Parry S; Patterson JE; Patterson TF; Patzer RE; Peluso MJ; Pemu P; Pettker CM; Plunkett BA; Pogreba-Brown K; Poppas A; Quigley JG; Reddy U; Reece R; Reeder H; Reeves WB; Reiman EM; Rischard F; Rosand J; Rouse DJ; Ruff A; Saade G; Sandoval GJ; Santana JL; Schlater SM; Sciurba FC; Shepherd F; Sherif ZA; Simhan H; Singer NG; Skupski DW; Sowles A; Sparks JA; Sukhera FI; Taylor BS; Teunis L; Thomas RJ; Thorp JM; Thuluvath P; Ticotsky A; Tita AT; Tuttle KR; Urdaneta AE; Valdivieso D; VanWagoner TM; Vasey A; Verduzco-Gutierrez M; Wallace ZS; Ward HD; Warren DE; Weiner SJ; Welch S; Whiteheart SW; Wiley Z; Wisnivesky JP; Yee LM; Zisis S; Horwitz LI; Foulkes AS;
JAMA; 2023 Jun; 329(22):1934-1946. PubMed ID: 37278994
[TBL] [Abstract][Full Text] [Related]
19. Acute and postacute sequelae associated with SARS-CoV-2 reinfection.
Bowe B; Xie Y; Al-Aly Z
Nat Med; 2022 Nov; 28(11):2398-2405. PubMed ID: 36357676
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
